Abbott Laboratories (ABT)
Health Care · Diversified Health Care · NYSE
A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions.
What Abbott Laboratories does
Abbott Laboratories is a global diversified health care company that develops, manufactures, and markets a broad range of products. Its business includes high-growth portfolios in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals.
Themes: diabetes care, cardiovascular health, diagnostic testing, medical devices, nutritionals, branded generics
Fundamentals
- Price$98.49 as of 2026-10-08 close
- Market cap$171.6B as of 2026-03-31 (share count; price 2026-10-08)
- 1-year return-26.6% 2025-10-08 close $134.27 → 2026-10-08 close $98.49
- P/E31.70 as of 2026-10-08
- Net margin+14.7% FY2025, SEC XBRL
- ROE+12.4% FY2025, SEC XBRL
- Debt / equity0.64 as of 2026-09-03
- Revenue growth (YoY)+8.1% as of 2026-09-03
- Revenue CAGR (3y)+0.5% SEC XBRL
- Beta0.18 as of 2026-09-03
- Last reported earnings2026-07-16 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +2.5%; at least 4 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How ABT compares in its sector
- price-to-earnings ratiomiddle range 185 covered Health Care peers, as of 2026-10-08
- net profit margintop 25% 430 covered Health Care peers, as of 2026-09-03
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-03
- return on equitytop 25% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldtop 25% 72 covered Health Care peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)top 10% 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ABT is not currently in any published Top 10 list. Its scores are below.
Top 10 score
46.0 #943 of 1,379 scored · #115 of 151 in Health Care
Profitability 61st (operating margin 18.2%, return on equity 12.4%) and financial health 58th (free cash flow margin 16.7%, debt to equity 0.6); weakest is trend (29th, over the past 12 months this stock lagged the market by 41.6 percentage points).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ABT's dividend was covered by reported results (earnings payout 63%, free-cash-flow payout 56%). This describes past coverage, not a forecast.
- Earnings payout63% dividends / net income
- Free-cash-flow payout56% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Abbott Laboratories looks technically
Abbott Laboratories (ABT) is trading 5.3% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30). It made a new 20-day low about 6 trading days ago. It is 27.2% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move.
Trend
7
| Distance from the 200-day | it is trading 5.3% below its 200-day average, the long-term trend line — a long-term downtrend | -5.3% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $106.29 | $106.29 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $104.01 | $104.01 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 15 trading days ago — a "golden cross", a bullish long-term signal | 15 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 30, with sellers in control | 30.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 38, neither overbought (above 70) nor oversold (below 30) | 37.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($95.06 to $104.54) — its "stochastic" reading is 36 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 36.2 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 30 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $135.37 | $135.37 |
|---|---|---|
| From the 52-week high | it is 27.2% below its 52-week high (its highest price of the past year) | -27.2% |
| Above the 52-week low | it is 20.2% above its 52-week low (its lowest price of the past year) | +20.1% |
| Below the 52-week high | it is 27.2% below its highest point of the past year | 27.2% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day high about 33 trading days ago | 33 sessions |
| All-time high | its highest closing price on record is $142.60 (set on 2021-12-27) | $142.60 |
| Given back of the 52-week move | over the past year its closes ranged ($82.56 to $134.59), and it has recovered roughly a third of its fall from last year’s high — 31% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $114.71 to $116.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 30.6% |
| From the all-time high | it is 30.9% below its all-time high | -30.9% |
| Nearest price level | it is trading 2.1% below a resistance level at $100.60 — a price it turned at twice since 2026-03-31, most recently on 2026-09-17. Since 2024-10-08 it has 0 such levels below the current price and 10 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +2.1% |
| All-time low | its lowest closing price on record is $9.82 (set on 1996-07-31) | $9.82 |
| Above the all-time low | it is 903.0% above its all-time low | +903.0% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 7% of the past ~6 months), which often precedes a bigger move | 7th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.34 between its high and its low — about 2.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.34 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $96.73 and $104.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $96.73 – $100.86 – $104.99 |
| Typical daily range (% of price) | its price moves about 2.4% in a typical session — calmer than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 2.4% |
| Stretch from the 200-day average | it is trading 2.4 daily ranges below its 200-day average price (5.3% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.33× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 0.3% since the prior reading | +0.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.07 toward buy |
Candlestick patterns
2
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 6.7% above the previous close 59 sessions ago and has not traded back through the level it left behind at 89.27 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +6.7% |
| Gap filled | a 2.0% gap up opened on 2026-08-03 has been "filled" 46 sessions ago — price traded back through the level the gap left behind, and it took 1 session to close | 46 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.7 percentage points (the stock lost 6.7% while the market gained 1.0%) | -7.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 0.3 percentage points (the stock gained 3.5% while the market gained 3.8%) | -0.3% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 21.2 percentage points (the stock lost 3.7% while the market gained 17.5%) | -21.2% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 41.6 percentage points (the stock lost 26.6% while the market gained 15.0%) | -41.6% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 3.7% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.4% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -3.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 3% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $101.30 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -2.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is 6% below the average price paid since it last reported on 2026-07-16 (its 8-K), so the typical buyer over that stretch is under water. That average is $104.96 — a volume-weighted average of daily closes over 60 sessions, not a true tick-by-tick VWAP. | -6.2% |
Price levels it has turned at before
ABT last closed at $98.49 on 2026-10-08. Since 2024-10-08 it has turned at 0 prices below its last close and 10 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $100.60 | Resistance | 2.1% above the last close | turned there twice · 2026-03-31 to 2026-09-17 |
| $104.55 | Resistance | 6.2% above the last close | turned there three times · 2026-01-28 to 2026-09-22 |
| $111.17 | Resistance | 12.9% above the last close | turned there five times · 2024-10-30 to 2026-07-29 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · lagging the market · Printed a doji candle | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.44 mean, 1=Strong Buy…5=Strong Sell) — 25 analysts
- Mean price target$120.58 range $103.00 – $135.00; median $120.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ABT
- Consensus EPS estimate$1.42 next reporting period, as of 2026-10-05
- Estimate change, 30 days+$0.00045 (+0.0%) from $1.42, on 2026-09-04, 31-day window
- Readings revised upward22% of 9 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Foreign currency exchange rate fluctuations affecting international operations.","Intense competition and pricing pressure in global health care markets.","Potential impact of regulatory, legal, and compliance proceedings."]
What changed in the latest 10-Q
AI-assisted comparison of ABT's 10-Q filed 2026-07-28 against the prior one filed 2026-04-29.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (filed 2026-07-28) includes sales tables for the three and six months ended June 30, 2026 and 2025, whereas the older filing (filed 2026-04-29) includes sales tables for the three months ended March 31, 2026 and 2025.
- Newer filing (filed 2026-07-28) includes six-month sales category detail by segment (e.g., Rhythm Management $1,427M, Diabetes Care $4,268M) that is absent from the older filing (filed 2026-04-29).
- Newer filing (filed 2026-07-28) states the Amplatzer Amulet transfer resulted in $101 million of sales in the first six months of 2025 being moved from Structural Heart to Electrophysiology; the older filing (filed 2026-04-29) states $46 million of sales in the first quarter of 2025 were reclassified.
- Newer filing (filed 2026-07-28) states that from the acquisition date of March 23, 2026, Diagnostic Products results included approximately $1.0 billion of sales from Exact Sciences reported as Cancer Diagnostics; the older filing (filed 2026-04-29) states Cancer Diagnostics results include Exact Sciences' net sales of $96 million from the acquisition date.
- Newer filing (filed 2026-07-28) adds commentary on six-month Established Pharmaceutical Products, Nutritional Products, Diagnostic Products, and Medical Devices sales performance for the first six months of 2026.
- Newer filing (filed 2026-07-28) states Core Laboratory sales grew in the U.S. and Latin America in the first six months of 2026; the older filing (filed 2026-04-29) states Core Laboratory sales grew across the U.S., Europe, and Latin America in the first three months of 2026.
- Newer filing (filed 2026-07-28) mentions the Exact Sciences acquisition drove the 12.2 percent increase in total net sales for the second quarter of 2026 excluding foreign exchange.
- Newer filing (filed 2026-07-28) includes second quarter 2026 discussion stating net sales were favorably impacted by foreign exchange with the weaker U.S. dollar increasing total international sales by 1.3 percent and total sales by 0.8 percent.
- Removed:
- Older filing (filed 2026-04-29) includes first quarter 2026 discussion of diabetes care growth in Abbott's continuous glucose monitoring (CGM) systems, with CGM systems sales totaling $2.0 billion and $1.7 billion in the first three months of 2026 and 2025; this CGM systems sales detail is absent from the newer filing (filed 2026-07-28).
- Older filing (filed 2026-04-29) includes first quarter 2026 segment-level commentary for Rhythm Management, Electrophysiology, Heart Failure, and Structural Heart (e.g., Aveir leadless pacemakers, Navitor and MitraClip products, multi-year agreement with a competitor); the newer filing (filed 2026-07-28) does not include this specific first quarter device-level commentary.
- Older filing (filed 2026-04-29) states Diagnostic Products sales increased 2.5 percent excluding foreign exchange in the first three months of 2026; the newer filing (filed 2026-07-28) does not repeat this first quarter percentage.
- Older filing (filed 2026-04-29) states total net sales increased 3.8 percent excluding foreign exchange during the first quarter of 2026; the newer filing (filed 2026-07-28) does not repeat this first quarter percentage.
- Older filing (filed 2026-04-29) includes a gross profit margin percentage discussion for the first quarter of 2026 (52.4 percent vs 52.8 percent) that appears at the end of the excerpt and has no counterpart in the newer filing (filed 2026-07-28).
- Reworded:
- Newer filing (filed 2026-07-28) describes the second quarter 2026 total net sales increase as driven by the Exact Sciences acquisition and high single-digit growth in Medical Devices and Established Pharmaceutical Products; the older filing (filed 2026-04-29) describes the first quarter 2026 increase as primarily reflecting higher product sales in Medical Devices and Established Pharmaceutical Products.
- Newer filing (filed 2026-07-28) states Nutritional Products sales in the first six months of 2026 decreased reflecting lower sales volumes across the adult nutritional and U.S. pediatric product portfolios; the older filing (filed 2026-04-29) states the first three months decline reflected lower sales volumes across both pediatric and adult nutritional product portfolios in the U.S. and internationally.
- Newer filing (filed 2026-07-28) states Established Pharmaceutical Products sales in Key Emerging Markets increased 10.1 percent in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 9.4 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Other Emerging Markets Established Pharmaceutical Products sales increased 4.9 percent in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 7.9 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Nutritional Products sales decreased 5.6 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they decreased 7.7 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Diagnostic Products sales increased 22.4 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 2.5 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Medical Devices sales increased 8.0 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 8.1 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Diabetes Care sales increased 8.2 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 7.4 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Core Laboratory sales increased 3.2 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they increased 3.3 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) states Rapid and Molecular Diagnostics sales decreased 8.8 percent excluding foreign exchange in the first six months of 2026; the older filing (filed 2026-04-29) states they decreased 9.6 percent in the first three months of 2026.
- Newer filing (filed 2026-07-28) describes Medical Devices growth in the first six months as led by double-digit growth in Electrophysiology, Rhythm Management, and Heart Failure; the older filing (filed 2026-04-29) describes first three months growth as led by double-digit growth in Rhythm Management, Electrophysiology, and Heart Failure (same segments, different order).
- Notes:
- The newer filing excerpt ends mid-sentence ('driven by continued growth in Abbott') and the older filing excerpt ends mid-sentence ('The decrease in the first three months of 2026 refl'), so changes appearing after these cut-off points cannot be assessed.
- The older filing (filed 2026-04-29) covers the three months ended March 31, 2026, while the newer filing (filed 2026-07-28) covers the three and six months ended June 30, 2026; differences in reported periods, percentages, and figures are expected and do not necessarily indicate restatements.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 4 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 4 sells ($47M) — 3 selling insiders
- Last 180 days · read to 2026-10-043 buys ($1M) · 4 sells ($47M) — 3 buying, 3 selling insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of ABT within a 30-day window between 2026-04-23 and 2026-05-07. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ABT's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 45 matched disclosures for ABT from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding ABT as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 271,792,785
- Reported value $24,662,477,244
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ABT's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ABT had 19,911,199 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ABT had 1.14% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.57 days to cover at the same settlement.
- Reported short interest (shares) 19,911,199
- Short interest (% of shares outstanding) 1.14%
- Prior settlement (shares) 22,129,750
- Reported change -10.03%
- Days to cover (reported) 2.57
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Medtronic (MDT)
- Johnson & Johnson (JNJ)
- Boston Scientific (BSX)
- Roche Holding (RHHBY)
- Danaher (DHR)
- Becton Dickinson (BDX)
- Stryker (SYK)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ABT vs…
Abbott Laboratories is found in…
ABT shows up in…
Frequently asked questions
What does Abbott Laboratories (ABT) do?
Abbott Laboratories is a global diversified health care company that develops, manufactures, and markets a broad range of products. Its business includes high-growth portfolios in diagnostics, medical devices, nutritionals, and branded generic pharmaceuticals.
What sector is Abbott Laboratories (ABT) in?
Abbott Laboratories (ABT) is classified in the Health Care sector. Its industry is Diversified Health Care. It trades on NYSE.
Does ABT pay a dividend?
Yes — Abbott Laboratories (ABT) pays a dividend, with an indicated yield of about 2.46% and at least 4 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are Abbott Laboratories's (ABT) competitors?
Notable peers of Abbott Laboratories (ABT) include Medtronic, Johnson & Johnson, Boston Scientific, Roche Holding and Danaher. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ABT?
Yes — we hold 45 matched STOCK Act disclosures for ABT from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Abbott Laboratories (ABT) overbought or oversold right now?
Abbott Laboratories (ABT) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 38, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ABT come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.